- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04025450
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
July 17, 2019 updated by: The First Affiliated Hospital of Soochow University
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients, a Phase I/II, Multiple Center, Randomized Clinical Trial
In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that of VRD regimen.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, which will be determined by efficacy and safety profiles of the patients; afterward, the optimal dosage of chidamide will be combined with VRD regimen, patients will be randomly assigned to chidamide+VRD group or VRD group, and their efficacy and safety will be compared.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chengcheng Fu, PhD
- Phone Number: 13962191404
- Email: fuzhengzheng@suda.edu.cn
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- Recruiting
- First Affiliated Hospital, SooChow University
-
Contact:
- Fu chengcheng, Phd
- Phone Number: 13962191404
- Email: fuchengcheng@suda.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
1.Diagnosed as multiple myeloma, and has one of the above:
- high risk karyotype, such as 17p-,t(4;14),t(14;16),t(14;20)或1q gain,1p-, double hit myeloma, triple hit myeloma, etc;
- RISS-3;
- IgD/IgE MM;
- with measurable extra-medullary plasmacytoma;
- flowcytometry showed peripheral blood plasma cell ≥0.165%;
2.Secretory MM should have measurable markers, including:
- specific M protein value (≥5g/L);
- and/or involved flc ≥100mg/L;
- and/or measurable extramedullary foci (diameter>1cm on CT);
- 3.Age≥18 years, male or female;
- 4.ECOG 0-2 points, with life expectance ≥3 months; GA score <2;
- 5.ALT/AST level <2.5 times of the maximum of normal range; total bilirubin<1.5 times of normal maximum;
- 6.Neutrophil count≥1.5×109/L, platelet count≥50×109/L;
- 7.eGFR≥40ml/min,except in the case of myeloma-related nephropathy;
- 8.Normal left ventricular ejaculation rate, NYHA stage 1, pulmonary function GOLD stage 1;
- 9.Willing to accept the possibility of potential adverse events and efficacy observation by the investigators;
- 10.Being able to understand and signing the written consent, which should be signed prior to any procedure of the trial.
Exclusion Criteria:
- 1.With ≥2 degree of peripheral neuropath or with pain;
- 2.Having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed;
- 3.With severe pulmonary/cardiac disfunction (including history of QT interval elongation, ventricular tachycardia, ventricular fibrillation, myocardial infraction) or other severe organ malfunction;
- 4.Patients in pregnancy or lactation;
- 5.Allergic constitution or being allergic to any drug within the regimen of the trial;
- 6.With uncontrolled mental diseases;
- 7.With active infection;
- 8.With non-myeloma-associated acute renal dysfunction;
- 9.With active hepatitis;
- 10.HIV positive;
- 11.History of other malignant tumor within 5 years prior to enrollment; except for the case of in situ cervical cancer and non-malignant melanoma;
- 12.With other conditions that the investigators think unfit for the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Chidamide plus VRD
Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
|
Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
|
ACTIVE_COMPARATOR: VRD
Velcade:1.3mg/m2
d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
|
Velcade:1.3mg/m2
d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
complete remission rate
Time Frame: at the time point 1 month after the last cycle
|
complete remission rate after treated by the corresponding regimen
|
at the time point 1 month after the last cycle
|
incidence and severity of adverse events
Time Frame: from the date of the start of treatment to 36 months after last patient's enrollment
|
any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure
|
from the date of the start of treatment to 36 months after last patient's enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: from the day of treatment to the date of first documented progression,up to 36 months after the last patient's enrollment
|
from the date of inclusion to date of death, irrespective of cause
|
from the day of treatment to the date of first documented progression,up to 36 months after the last patient's enrollment
|
progression free survival
Time Frame: from the day of treatment to the date of first documented progression,up to 36 months after the last patient's enrollment;
|
from date of inclusion to date of progression, relapse, or death from any cause
|
from the day of treatment to the date of first documented progression,up to 36 months after the last patient's enrollment;
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: chengcheng Fu, PhD, First Affiliated Hospital of Suzhou University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
July 15, 2019
Primary Completion (ANTICIPATED)
July 15, 2029
Study Completion (ANTICIPATED)
July 15, 2029
Study Registration Dates
First Submitted
July 17, 2019
First Submitted That Met QC Criteria
July 17, 2019
First Posted (ACTUAL)
July 19, 2019
Study Record Updates
Last Update Posted (ACTUAL)
July 19, 2019
Last Update Submitted That Met QC Criteria
July 17, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- SZ-ChiVRD VS VRD-MM02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Chidamide+VRD
-
Medtronic Neurovascular Clinical AffairsCompletedIntracranial Bifurcating AneurysmsUnited States
-
Codman & ShurtleffCompletedA Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial ArteriesAtherosclerosis | AneurysmArgentina
-
Kobe City General HospitalUnknown
-
Medtronic Neurovascular Clinical AffairsCompleted
-
Huiqiang HuangUnknownLymphoma, Extranodal NK-T-Cell | EBV
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Codman & ShurtleffCompletedIntracranial AneurysmBelgium
-
Sun Yat-sen UniversityRecruitingTriple Negative Breast CancerChina
-
Sun Yat-sen UniversityUnknown
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRelapsed/Refractory PTCLT With at Least One Line of Prior Systemic TherapyChina